A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

Quilizumab, a humanized IgG1 monoclonal antibody, targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. In patients with mild asthma, quilizumab reduced serum IgE and attenuated the early and late asthmatic reaction following whole lung alle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory research 2016-03, Vol.17 (29), p.29-29, Article 29
Hauptverfasser:	Harris, Jeffrey M, Maciuca, Romeo, Bradley, Mary S, Cabanski, Christopher R, Scheerens, Heleen, Lim, Jeremy, Cai, Fang, Kishnani, Mona, Liao, X Charlene, Samineni, Divya, Zhu, Rui, Cochran, Colette, Soong, Weily, Diaz, Joseph D, Perin, Patrick, Tsukayama, Miguel, Dimov, Dimo, Agache, Ioana, Kelsen, Steven G
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adolescent Adrenal Cortex Hormones - administration & dosage Adult Aged Allergens Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - adverse effects Antibodies, Anti-Idiotypic - administration & dosage Antibodies, Monoclonal - administration & dosage Asthma Asthma - diagnosis Asthma - drug therapy Asthma - immunology Care and treatment Clinical trials Combined Modality Therapy Complications and side effects Corticoids Corticosteroids Dose-Response Relationship, Drug Female Health aspects Humans Hypersensitivity - diagnosis Hypersensitivity - drug therapy Hypersensitivity - immunology Influence Lungs Male Middle Aged Nitric oxide Pharmacokinetics Respiratory function Safety Secondary Prevention - methods Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!